ISM9077

ISM9077 is a preclinical-stage, AI-designed small molecule inhibitor developed by Insilico Medicine. Discovered and optimized using the Chemistry42 generative AI platform, the compound targets a protein designated as "Target Y," which plays a critical role in pathological inflammation. ISM9077 is primarily positioned for the treatment of ocular diseases, including dry age-related macular degeneration (dry AMD), uveitis, and dry eye disease, benefiting from high retinal tissue exposure that reaches up to 5.5 times plasma levels. The drug is designed for versatility in administration, supporting both oral and topical (eye drop) delivery. Beyond ophthalmology, Insilico is exploring its potential in a wide range of inflammatory and aging-related conditions, such as neurodegeneration, inflammatory bowel disease, cardiovascular disease, MASH, and obesity. Preclinical data indicates a favorable safety profile and superior efficacy compared to standard-of-care treatments like Cyclosporine A in dry eye models.